NANOBIOTIX Welcomes New Board Members for Future Growth
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX) is pleased to announce the addition of two distinguished individuals to its Supervisory Board. This strategic decision is designed to reinforce the company’s foundation for sustainable, long-term growth in the biotechnology sector.
Introducing the New Board Members
Dr. Margaret A. Liu and Ms. Anat Naschitz are both highly regarded professionals in their fields. Dr. Liu is internationally recognized for her expertise in vaccines, gene therapy, and cancer immunotherapy, and currently holds the position of CEO at PAX Therapeutics. Her impressive career includes significant roles at leading organizations where she has made major contributions to the development of DNA vaccines and bispecific antibodies.
Ms. Anat Naschitz, a veteran life science investor and entrepreneur, brings over three decades of experience across various biotechnology sectors. As the co-founder of 9xchange, she utilizes artificial intelligence to enhance biopharma assets, demonstrating her dedication to innovation in healthcare.
Strategic Vision for Oncology
Laurent Levy, Ph.D., CEO of NANOBIOTIX, stated that the addition of experts like Dr. Liu and Ms. Naschitz aligns perfectly with the company's mission to advance therapies based on nanophysics for cancer treatment. Their combined expertise is expected to strengthen strategic initiatives for NBTXR3 and create new opportunities for collaboration and development.
Dr. Margaret A. Liu’s Achievements
Dr. Liu’s career highlights include her role as a Principal at ProTherImmune and key positions at Merck & Co. and Chiron Corporation. She has received numerous international accolades for her pioneering work and serves on the boards of several prestigious organizations in the realms of vaccines and biotechnology.
Anat Naschitz’s Entrepreneurial Path
Ms. Naschitz's remarkable career features co-leading OrbiMed Israel and investing in various healthcare innovations. She has a solid track record of supporting companies through critical growth stages, showcasing her expertise in navigating the complexities of the biopharmaceutical industry.
Looking Ahead
Both Dr. Liu and Ms. Naschitz are expected to play crucial roles in shaping the future of NANOBIOTIX as the company continues to pursue innovative cancer therapies. Their insights and experiences are anticipated to enhance the company’s strategic framework, ensuring it remains at the forefront of advancements in biotechnology.
About NANOBIOTIX
NANOBIOTIX is a late-stage clinical biotechnology company dedicated to developing groundbreaking, physics-based therapeutic approaches. With a commitment to improving lives, NANOBIOTIX aims to redefine treatment options for cancer patients through the innovative application of nanotechnology.
Founded in 2003 and based in Paris, France, NANOBIOTIX has extended its presence with subsidiaries in key locations, including Cambridge, Massachusetts. The company holds over 25 umbrella patents across three pioneering nanotechnology platforms focused on oncology, enhancing bioavailability, and addressing disorders of the central nervous system.
Frequently Asked Questions
Who are the new board members of NANOBIOTIX?
The new board members are Dr. Margaret A. Liu and Ms. Anat Naschitz, both of whom have extensive backgrounds in biotechnology.
What positions do Dr. Liu and Ms. Naschitz hold?
Dr. Liu serves as the CEO of PAX Therapeutics, while Ms. Naschitz is the co-founder and CEO of 9xchange.
Why are these appointments important?
These appointments are significant as they strengthen NANOBIOTIX’s strategic efforts in oncology and promote collaboration.
What is the mission of NANOBIOTIX?
NANOBIOTIX aims to lead the development of therapies that transform treatment outcomes for cancer patients through innovative nanotechnology.
Where is NANOBIOTIX’s headquarters located?
NANOBIOTIX is headquartered in Paris, France, and has additional subsidiaries around the globe.
